Hemolytic uremic syndrome (HUS) after transplantation is difficult to treat, and there is no consensus regarding optimal mode of treatment. We attached transdermal isosorbide tape as a nitric oxide (NO) donor to patients with HUS after bone marrow transplantation (BMT). This was very effective in ameliorating the hemolysis and increasing platelet numbers. We report here the successful use of an isosorbide in a patient with HUS after transplantation. Bone Marrow Transplantation (2000) 25, 109-110.
Allogeneic hematopoietic stem cell transplantation is sometimes complicated by the occurrence of hemolytic uremic syndrome (HUS) caused by damage to endothelial cells in the kidney. [1] [2] [3] [4] [5] [6] These cells can be easily damaged by radiation therapy or anti-cancer drugs such as alkylate. 1, 5 There are various types of HUS ranging from slight effects on renal function to complete renal failure.
We report here a case of HUS following allogenic hematopoietic stem cell transplantation. In HUS, the kidney is usually hyperechoic on ultrasonography. In this patient, however, the kidney was hypoechoic and therefore this case appeared to differ from common HUS. Nitric oxide (NO) protects endothelial cells within the blood vessels. Therefore, we applied transdermal isosorbide tape to this patient. The HUS in this patient was improved by this procedure suggesting that isosorbide may be useful for treatment of patients with HUS.
Case report
The patient was a 9-year-old girl. At the age of 8 months, an abdominal tumor was found in her left hypochondrial region. The mass was about 3 × 3 cm, hard, and its surface was irregular. The lesion increased in size and a diagnosis of left adrenal neuroblastoma was made based on the results of abdominal ultrasonography, computed tomography, high levels of serum neuron-specific enolase and high urinary levels of vanillylmandelic acid. Although she received chemotherapy for about 1 year after resection of the tumor, she had a relapse at the age of 2 years and 3 months. Due to this recurrence, chemotherapy was continued until the age of 5 years and 9 months. One year and 7 months after the therapy ended, platelet counts in her peripheral blood had decreased.
On admission, her peripheral blood findings showed a hemoglobin level of 9.2 g/dl, a platelet count of 5.0 × 10 4 /l, and a white blood cell count of 5900/l. Serum chemistry was within normal limits. The mononuclear cell count of bone marrow was 4.4 × 10 4 /l with 1.8% myeloblasts and 0.4% promyelocytes. Smears from bone marrow aspirate revealed hyposegmentation, agranulocytes and micromegakaryocytes. The chromosomes of the blast cells showed 47, X, −X, +der (X; 3) (p10; q10), +der (1; 4) (p10, q10), add (2) (q1?), add (12) (q11), −14, +mqr.
A diagnosis of myelodysplastic syndrome (refractory anemia) was made. Five months later, the patient received a bone marrow transplant from her identical twin sister. Four months after transplant, the peripheral blood platelet count and hemoglobin level fell. Laboratory blood tests showed a hemoglobin level of 10.3 g/dl, a platelet count of 3.7 × 10 4 /l, and a white blood cell count of 5500/l with 4.2% reticulocytes. However, 1 month previously she had had a hemoglobin level of 9.1 g/dl, a platelet count of 17.8 × 10 4 /l, and a white blood cell count of 4500/l. Serum chemistry showed high levels of total bilirubin (1.0 mg/dl), lactate dehydrogenase (LDH, 1926 IU/l; normal range: 259-481 IU/l), creatinine (0.8 mg/dl) and blood urine nitrogen (BUN, 51 mg/dl). Serum haptoglobin level was decreased to 10 mg/dl or less. Urinalysis revealed hemoglobinuria and proteinuria (70 mg/dl). Coombs' test and anti-platelet antibodies were negative. Helmet cells were detected in smears from peripheral blood. A bone marrow aspirate was normal. A diagnosis of HUS was made, and she was treated with transdermal isosorbide tape (20 mg/day; Yamanouchi Pharmaceutical, Tokyo, Japan) with her parents' informed consent. The platelet count began to increase on the first day, and the hemolysis improved. Her renal function recovered slowly. Anticoagulant (heparin 100 IU/kg/day for 7 days, and nafamos- tat mesilate, an ultrashort-acting multi-enzymatic inhibitor, 2.4 mg/kg/day for 7 days) was given but treatment was stopped because there was no improvement in her condition. Hypotension and secondary tachycardia were not observed with administration of the isosorbide. The patient showed no side-effects from the transdermal isosorbide tape, and completely recovered from HUS ( Figure 1 ).
Discussion
Isosorbide has been used for treatment of patients with myocardial ischemia. Nitroglycerine and isosorbide produce NO, a naturally occurring free radical gas that can relax vascular smooth muscle through the endothelium. [7] [8] [9] Isosorbide enhances prostaglandin generation from endothelial cells, 10 and inhibits platelet aggregation. 11 NO expands the vessels and inhibits platelet function. An ideal method for treatment of HUS would induce expansion of narrow blood vessels and inhibition of platelet coagulation. We applied transdermal isosorbide tape as a NO donor to a patient with HUS after BMT. Good effects were observed from the first day of treatment, and the patient showed no disease recurrence on cessation of isosorbide treatment.
The method described here was very effective for treatment of HUS, and was accompanied by no side-effects.
